
B. Riley lowered the firm’s price target on Microbot Medical (MBOT) to $3 from $4 and keeps a Buy rating on the shares. Microbot’s Q3 LIBERTY revenue fell sharply on
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MBOT | Microbot Medical | 0.68 | -1.15 | -62.84% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.68 | -62.84% |

B. Riley lowered the firm’s price target on Microbot Medical (MBOT) to $3 from $4 and keeps a Buy rating on the shares. Microbot’s Q3 LIBERTY revenue fell sharply on

Citizens lowered the firm’s price target on Microbot Medical (MBOT) to $2 from $2.50 and keeps an Outperform rating on the shares. Microbot’s revenue fell roughly 70% sequentially due to

Microbot Medical ( ($MBOT) ) has shared an update. On November 16, 2026, Microbot Medical said it had filed its quarterly report for the period ended September 30, 2026. It

Microbot Medical (MBOT) announced that the Canadian Intellectual Property Office, or CIPO, granted the company a patent for an adaptor for coupling a proximal portion of an elongate surgical tool

An update from Microbot Medical ( ($MBOT) ) is now available. On November 5, 2026, Microbot Medical announced that the Canadian Intellectual Property Office had granted it a patent for

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Microbot Medical and keeping the price target at $12.00. Ram Selvaraju has given his Buy rating due to a

Microbot Medical (MBOT) announced that ELMNT IR, a multisite outpatient interventional radiology practice in California, has signed an order to purchase up to a 12-month supply of Liberty devices. ELMNT

An announcement from Microbot Medical ( ($MBOT) ) is now available. On October 27, 2026, Microbot Medical announced that California-based ELMNT IR, a multisite outpatient interventional radiology practice, ordered up

Microbot Medical ( ($MBOT) ) just unveiled an announcement. On October 23, 2026, Microbot Medical Inc. announced that its executives and commercial team would attend the SIR EDGE 2026 conference

Citizens initiated coverage of Microbot Medical (MBOT) with an Outperform rating and $2.50 price target The company is entering the early stages of commercialization with Liberty, the first single-use, remotely
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.